Aim of the work: 
ml/min), adequate hepatic function (serum bilirubin level ≤2.0 mg/ml, serum aspartate and alanine transaminase (AST and ALT) levels ≤2.5 times upper normal limit or ≤5 times upper normal limit if liver metastases or biliary drainage were present). Exclusion criteria included: symptomatic pulmonary fibrosis or interstitial pneumonia, marked pleural effusion or ascites, central nervous system metastasis, active concomitant malignancy, severe mental disorder, serious complications such as active infection, active gastrointestinal ulcer, or cardiac disease and pregnant or lactating women.
Treatment plan:
The patients received gemcitabine at dose of 1000mg/m 2 intravenously (IV) over 30 min on days 1 and 8, and cisplatin at dose of 80 mg/ m 2 just after gemcitabine over 2 hours on day 1 as IV infusion after IV prehydration with 1 liter of 0.9% sodium chloride containing 20 mmol potassium chloride and 1gram of magnesium sulphate. After cisplatin administered, at least 2 liter of saline as post-hydration to maintain a urine output of 100ml/h during and for 6-8 hours after cisplatin administration.
The treatment cycles were repeated every 3 weeks for a maximum of six cycles unless disease progression or unacceptable toxicity occurred. Standard antiemetic treatment with ondansetron was given to all patients only on the day of administration of chemotherapy. Dose reduction of gemcitabine from 1000mg/m 2 to 800mg/m 2 was allowed when patients experiend grade 4 leukopenia or neutropenia, grade 3 thrombocytopenia requiring blood transfusion, febrile neutropenia, or grade 3 or 4 non-hematological toxicities other than nausea, vomiting, anorexia and hyperglycemia.
Patient evaluation
Prior to treatment, each patient was evaluated by medical history, physical examination, full blood cell count, blood chemistry, tumor markers (CEA and CA 19.9) and urine analysis. Computed tomography (CT) scans of chest and abdomen were also performed.
Karnofsky performance status, weight, disease-related symptoms and especially pain, as well as analgesic consumption, were evaluated at base line and at the completion of second, fourth and sixth cycle of chemotherapy thereafter.
During chemotherapy, full blood counts with differential and biochemical test were performed before each cycle of chemotherapy. CT scan or MRI was done every 3 cycles of chemotherapy to assess objective response. Patients underwent follow-up examination every 2 months. Tumor response was evaluated using the criteria of the world health organization (WHO) (15) . Toxicities were graded according to the National Cancer Institute common toxicity criteria version 2.0 (16).
Study end points:
The primary end points were the assessment of response rate and clinical benefit. Secondary end points included survival, time to progression and toxicity.
Clinical benefit response is composite assessment of clinical parameters including pain, PS and weight loss, and was evaluated according to previously established criteria (3) . The assessment of pain relief was based on both the consumption of analgesics and the patient own evaluation of pain using an optical scale graded from 0 (no pain) to 10 (maximum pain necessitating analgesics for relief (3) .
Pain improvement was characterized by a > 50% reduction in analgesic consumption coupled with the patient own evaluation of > 50% decrease in pain intensity. Pain deterioration was defined as any increase of initial pain intensity by > 50% of the patients own evaluation prior to treatment, coupled with increased or at least stable analgesic consumption.
Improvement in PS was denoted as ≥ 20 points from above baseline, and weight gain ≥ 7% from baseline sustained for ≥ 4 weeks (3).
For patients to achieve an overall rating of positive clinical benefit response, they had to be positive for at least one parameter (pain, performance status, or weight) without being negative for any of the others. This improvement had to last for at least 4 weeks.
Time to tumor progression (TTP) was calculated from the date of the start of therapy until documented disease progression or death owing to any cause, whichever occurred first. For patients still alive at the time of analysis and who did not have disease progression, TTP was censored at the date of the last follow-up visit. Overall survival was calculated from the date of the start of therapy to the date of death owing to any cause. Patients alive on the date of the last follow-up visit were censored on that date. Median survival and the median TTP were estimated by the Kaplan-Meier method.
III.
Results:
Patient's characteristics
Twenty-five patients (19 male, 6 female) with unresectable or metastatic pancreatic cancer were enrolled in this study between August 2003 and December 2005. The patient characteristics are shown in Table  1 .The Median age was 52 years; (range 36-68). Before the start of the treatment, the majority of patients (84%) had stage IV disease and 15 (60%) patients had liver metastases. Four (16%) patients had undergone surgical resection and seven (28%) patients had undergone biliary drainage for obstructive jaundice. Abdominal and/or back pain was the most common initial symptoms among 19(76%) patients, followed by weight loss (60%), and anorexia (40%) before treatment. The karnoksky PS was as follows: 80-70% in 3(12%) patients, 70-60 % in 7(28%) patients, and 60-50 % in 15(60%) patients.
Treatments
A total of 96 cycles were administered to the 25 patients with a median of 3 cycles per patient (range 2-6). Gemcitabine was administered on day 8 in 83 (86%) of the 96 cycles. Gemcitabine dose reduction was required in 4(16%) patients owing to grade 3-4 hematological toxicity, and in 2(8%) patients due to elevated hepatic enzymes (grade 3).
Response to treatment and survival
There were no complete responses observed. Five patients (20%) achieved partial responses (PR), Stable disease (SD) was observed in 16 patients (64%). Progressive disease (PD) was observed in four patients (16%), two of them after the third cycle of treatment accompanied with increase pain intensity and deterioration of performance status. table (2) .
At the time of analysis, all the patients were confirmed to be dead. The cause of death was disease progression in all cases. With a median follow up of 4 months, (range 3-12). The median TTP was 4.6 months and the median overall survival was 7.1 months with a 1-year survival rate of 20% ( Fig. 1 & 2) .
Clinical Benefit response
Clinical benefit response data are summarized in table 2. Nineteen (76%) patients had severe pain prior to treatment. All patients consumed analgesic in the form of either NSAIDs (14 patients) or tramadol HCL (5 patients) prior to treatment. After the second cycle of chemotherapy 8 of 19 patients (42%) experienced pain intensity improvement > 50% and reduced the daily dose of analgesic by >50%. Six (31.5%) patients remained stable and 5 (26.3%) patients worsened. All patients had Karnofsky PS 80% or less before the treatment. Improved Karnofsky PS by >20% points from baseline was observed in five of 21 patients (23.8%) after the second cycle of chemotherapy, whereas 13(61.9%) patients remained stable and 3 (14.2%) worsened. After the end of six cycle of chemotherapy, 13 (68.4%) patients out of 19 showed improved Karnofsky PS. Fifteen (60%) patients had significant weight loss before treatment. After the second cycle of chemotherapy 5 out of 15 patients (33.3%) experienced a weight gain of at least 7%, this percent was elevated up to 76.9% (10 out 13 patients) at the end of treatment. The median time to achieve a clinical benefit response was 6 weeks.
Toxicity
All 25 patients were evaluated for toxicities during treatment, which are listed in Table ( 2). The most common toxicities were myelosuppression, especially neutropenia and thrombocytopenia. Grade 3-4 neutropenia and thrombocytopenia occurred in 52 and 48% of the patients, respectively. Most of these hematologic toxicities were transient and reversible. Three patients required hospitalization as a result of grade 4 neutropenia and fever. No other unexpected severe toxicities were observed during the study and there were no treatment-related deaths. Although gastrointestinal toxicities such as nausea, vomiting and anorexia were frequently observed after cisplatin administration, most of them were manageable with appropriate medical treatment. 
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IV. Discussion:
Pancreatic cancer is one of the most chemotherapy-resistant tumors. For many years, 5-FU was been the drug of choice in treating patients with pancreatic cancer, with objective responses ranging from 0%-60% in different published studies. (3) In the mid 1990s, gemcitabine was approved for treatment of metastatic pancreatic cancer (3). The strategy to improve the treatment of advanced and metastatic pancreatic cancer since then has been focused on adding a second agent to gemcitabine. We conducted the present study to evaluate the efficacy and toxicity of gemcitabine and cisplatin combination therapy in twenty-five Egyptian patients with metastatic pancreatic cancer. According to results of our study, this combination therapy seems to be effective and well tolerated. No complete responses were documented, but partial response was achieved in 20% of patients and stable disease was observed in 64% of patients. The positive impact of the gemcitabine and cisplatin combination chemotherapy is reflected by the observed median survival of 7.1 months in our patients.
For most cancer, tumor-related symptoms are closely related to tumor bulk, in pancreatic cancer even small reductions in tumor size may result in significant clinical benefit as a result of the location of the tumor (27) .In this respect, gemcitabine has been proved by many studies to be more effective than standerd 5-FU chemotherapy in treatment patients with pancreatic cancer. (28) Partial response and stable disease in combination with clinical benefit response was reasonable treatment goal in patients with pancreatic cancer. In our study, after second cycle chemotherapy, clinical benefit response was observed in most of patients. Pain improved in 42% of patients, with >50% reduction of analgesic consumption. Karnofsky PS improved by>20% in 23.8% of patients, and 33.3% experienced a weight gain of >7% from baseline.
(OS) were still disappointing. The median TTP and OS in the current study were 4.6 and 7.1 months respectively, which is comparable with the published studies of this combination, where the range of TTP was between 3.6 to 7.4 months, and the range of OS was between 5.6 to 9.6 months (17-23). But, both TTP and OS in the combination studies were better than those reported in most studies of gemcitabine monotherapy for advanced pancreatic cancer (TTP 2-3 months, overall survival about 6 months) (3-5).
The major toxicity of the gemcitabine and cisplatin combination is myelosuppression. In many studies using this combination, the incidence of grade 3-4 neutropenia and grade 3-4 thrombocytopenia were between 50% and 68% (17) (18) (19) (20) (21) (22) (23) . Hematological toxicity in our study was also high, with a 52% incidence of grade 3-4 neutropenia and a 48% incidence of thrombocytopenia. Although the incidences of G3-4 neutropenia and thrombocytopenia in our study were high, most of such episodes were transient and resolved spontaneously, except in three patients were required hospitalization as a result of grade 4 neutropenia.
The plateau of efficacy results with gemcitabine combinations with standard cytotoxic drugs suggest that this strategy should be superseded by the study of novel therapeutic approaches in order to improve the prognosis of patients with pancreatic cancer. Recent data with the angiogenesis inhibitor bevacizumab and the EGFR-1 inhibitors cetuximab and erlotinib hold hopes that a paradigm shift in the management of advanced pancreatic cancer is forthcoming (24) (25) (26) .
